Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know Corcept Therapeutic
Corcept Therapeutics reported Q2 revenue of $256.1 million, up from $194.4 million a year earlier, beating analyst estimates of $219.32 million by 16.8%, and EPS of $0.36 versus $0.02 expected. The company said Lifyorli generated $47.6 million in its first full quarter and raised full-year revenue guidance to $1.1 billion to $1.2 billion.
How this was made
The 30-second read
Why it matters
The combination of a large EPS beat, revenue beat, and a raised full-year revenue guidance range is a direct re-rating catalyst for CORT, with Lifyorli sales and patient starts providing a concrete demand narrative.
Market read
This is a company-specific earnings and guidance reset with a product-driven sales update, explaining the after-hours jump and setting new forward expectations.
What to watch
The article does not quantify margins, cash flow, or competitive dynamics; traders may later focus on sustainability of the $47.6M first full-quarter Lifyorli sales and any safety or reimbursement headwinds.
Background
Corcept is a biopharmaceutical company with oncology and Cushing’s syndrome franchises; Lifyorli received FDA approval in March and is now reporting its first full quarter post-approval.
Ticker impact
Corcept reported Q2 revenue of $256.1M and EPS $0.36, far above expectations, and raised full-year revenue guidance to $1.1B-$1.2B.
Likely continued volatility and upside bias in the next session as traders reprice guidance and Lifyorli uptake.
The article discloses hard numbers (revenue, EPS, guidance range) and a product-specific driver (Lifyorli first full quarter since FDA approval) that directly affect valuation and forward estimates.
Market effects
Biopharma sentiment may improve at the margin for oncology names if Lifyorli demand signals durable uptake post-approval.
Limited, primarily US small/mid-cap biotech sentiment rather than a broad regional macro driver.
Low global spillover; impact is mostly company-specific unless peers cite similar post-approval traction.
Counterpoint
The EPS beat may be less durable than revenue growth, and guidance could prove conservative if Lifyorli ramp slows after the initial post-approval period.
Key entities
- companyCorcept Therapeutics
Subject of the article; reported Q2 results, highlighted Lifyorli performance, and raised full-year revenue guidance.
- productLifyorli
Oncology drug used with nab-paclitaxel; generated $47.6M in its first full quarter since FDA approval and has 1,300+ patients started.
- executiveJoseph Belanoff
CEO quoted saying oncology and Cushing’s syndrome businesses delivered strong results in the quarter.
